Patient (pt) population and radiation therapy (RT) type in the long-term phase 3 double-blind, placebo (PBO)-controlled ATLAS study of apalutamide (APA) added to androgen deprivation therapy (ADT) in high-risk localized or locally advanced prostate cancer (HRLPC).

Howard M. Sandler, Felix Y. Feng, Neal D. Shore et al.|Journal of Clinical Oncology|2022

Cited by 9